Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor with Chemoradiation in Rectal Cancer
NCT02137356Phase 1Unknown
- Sponsor
- Sheba Medical Center
- Start
- Dec 2014
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of selinexor in rectal cancer, sponsored by Sheba Medical Center. Primary endpoint: Number of patients with adverse events at 6 weeks. Status: unknown.
02
Drugs
selinexor
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT02137356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02137356.